Overview

Location [1]
12q13.12
Pathway
Chromatin remodeling/DNA methylation
Protein [2]
Histone-lysine N-methyltransferase 2D
Synonyms [1]
MLL4, AAD10, KABUK1, MLL2, KMS, ALR, TNRC21, CAGL114

Lysine (K)-specific methyltransferase 2D (KMT2D) is a gene that encodes a protein that functions as a histone methyltransferase that methylates the LYS-4 position of histone H3. Missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as intestine cancer, skin cancer, and stomach cancer.

KMT2D is altered in 8.52% of all cancers with lung adenocarcinoma, colon adenocarcinoma, bladder urothelial carcinoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].

KMT2D GENIE Cases - Top Diseases

The most common alterations in KMT2D are KMT2D Mutation (10.28%), KMT2D P2354Lfs*30 (0.14%), KMT2D P647Hfs*283 (0.09%), KMT2D Amplification (0.08%), and KMT2D G1235Vfs*95 (0.08%) [3].

KMT2D GENIE Cases - Top Alterations

Significance of KMT2D in Diseases

Medulloblastoma +

Malignant Solid Tumor +

Bladder Carcinoma +

Lymphoma +

Melanoma +

Esophageal Squamous Cell Carcinoma +

Colorectal Carcinoma +

Non-Small Cell Lung Carcinoma +

Gastric Adenocarcinoma +

Esophageal Adenocarcinoma +

Ovarian Carcinoma +

Glioblastoma +

Breast Carcinoma +

Anaplastic Astrocytoma +

Sarcoma +

Pancreatic Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Gastric Squamous Cell Carcinoma +

Head And Neck Carcinoma +

Intracranial Primitive Neuroectodermal Neoplasm +

Medulloblastoma, Non-WNT/Non-SHH +

Medulloblastoma, SHH-Activated +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20171026. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.